The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2018 | A multitude of new CLL drugs: how to choose?
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Anthony Mato, MD, MSCE, from Memorial Sloan Kettering Cancer Center, New York, NY, gives his insight on the challenges of finding more effective treatment options for chronic lymphocytic leukemia (CLL). More and more chemotherapy agents are being approved for the treatment of CLL, so effective measures need to be put in place to ensure the safety of these novel therapies when used in combination with existing drugs, utilizing retrospective data and existing clinical trial results. Dr Mato also explains how updating the current literature on novel CLL therapies will facilitate decision making when choosing appropriate therapies for the frontline and relapsed/refractory settings.
